(Q24235577)

25 October 2023

2

Emmanuel Tsochatzis

Emmanuel

Tsochatzis

1 reference

25 October 2023

3

Brian R Davidson

Brian R

Davidson

1 reference

21154370

25 October 2023

Andrew Kenneth Burroughs

4

Andrew K Burroughs

Andrew K

Burroughs

1 reference

21154370

Cochrane Database of Systematic Reviews

25 October 2023

publication date

8 December 2010

0 references

published in

0 references

cites work

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Daily interferon Alpha-2B and ribavirin combination therapy for liver transplant patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Combination therapy of interferon alpha-2B and ribavirin for recurrent hepatitis C after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Pre-emptive treatment of recurrent hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Prevention and treatment of hepatitis C virus recurrence after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Hepatitis C, interferon, and risk of rejection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

A model to predict severe HCV-related disease following liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Ribavirin plus interferon versus interferon for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

The association between hepatitis C infection and survival after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Antiviral therapy for recurrent liver graft infection with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

A model to predict survival in patients with end-stage liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Ischemic preconditioning in deceased donor liver transplantation: a prospective randomized clinical trial of safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

A comparison of methods to detect publication bias in meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Intention-to-treat analysis: implications for quantitative and qualitative research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Liver and intestine transplantation in the United States, 1995-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

The influence of viral genotypes and rejection episodes on the recurrence of hepatitis C after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

Effect of ischemic preconditioning in whole liver transplantation from deceased donors. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

7 January 2021

Early ribavirin treatment and avoidance of corticosteroids in hepatitis C virus (HCV)-positive liver transplant recipients: interim report of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

7 January 2021

Recurrence of HCV infection in liver transplant patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

7 January 2021

Recurrence of hepatitis C in liver transplants from elderly donors aged more than 75 years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

7 January 2021

Chronic hepatitis C after liver transplantation: a randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

7 January 2021

Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

7 January 2021

Extended right split liver graft for primary transplantation in children and adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006573.PUB2

7 January 2021

10.1002/14651858.CD006573.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_mxnumtlgojhchir5udnqdx5bne

0 references